Plus India Formulation Private Limited
About Plus India Formulation Private Limited
Data last updated:
Plus India Formulation Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 September 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U52110TG2021PTC154953.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Sudhakara Reddy Kalakota and Rama Devi Kalakota.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at First Floor Plot No 15 Pradampuri Colony Kapra Ecil Post, Hyderabad, Telangana, India – 500062.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.55 Cr, a growth of 5% compared to the previous year. For the same year it recorded a net profit of ₹3.28 Lakh (net margin 0.9%) and EBITDA of ₹4.5 Lakh (EBITDA margin 1.3%). Revenue has grown at a compounded annual rate (CAGR) of 65% over three years.
As per MCA filings, the company has open charges of ₹50 Lakh on record.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressFirst Floor Plot No 15 Pradampuri Colony Kapra Ecil Post, Hyderabad, Telangana, India – 500062
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Plus India Formulation Private Limited
The main business activity of Plus India Formulation is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Plus India Formulation Private Limited FY 2025 filings available
Plus India Formulation Private Limited reported revenue of ₹3.55 Cr (up 5% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Plus India Formulation Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 65% over three years, including 5% growth in the latest year. EBITDA rose 11% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Plus India Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• |
| EBITDA | ₹4.5 Lakh | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹3.28 Lakh | •••• | •••• | •••• |
| Balance Sheet | ||||
| Share Capital | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• |
Financial Ratios of Plus India Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 1.3% | •••• | •••• | •••• |
| Net Profit Margin | 0.9% | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• |
| Liquidity and Debt | ||||
| Current Ratio | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• |
| Efficiency and Growth | ||||
| Asset Turnover | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Plus India Formulation are in the company report.
Financial statements from FY 2022
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Plus India Formulation Private Limited
Plus India Formulation Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Genext Healthcare Private Limited | ₹3.57 Cr (FY 2025) | •••• | •••• | -21.0% | •••• | Guwahati, Assam, India |
| Shirr Pharmaceuticals Private Limited | ₹3.57 Cr (FY 2025) | •••• | •••• | 2.0% | •••• | Thiruvananthapuram, Kerala, India |
| Laxor Pharma Private Limited | ₹3.57 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Ahmedabad, Gujarat, India |
| Aayush Medication Private Limited | ₹3.55 Cr (FY 2024) | •••• | •••• | 4.0% | •••• | Vapi, Gujarat, India |
| Lohitha Chemtek Private Limited | ₹3.55 Cr (FY 2025) | •••• | •••• | 212.0% | •••• | Hyderabad, Telangana, India |
| Plus India Formulation Private Limited this company | ₹3.55 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Hyderabad, Telangana, India |
| Cuidado Medico Private Limited | ₹3.54 Cr (FY 2025) | •••• | •••• | 46.0% | •••• | Ahmedabad, Gujarat, India |
| Grefith Industries Private Limited | ₹3.53 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Chandigarh, India |
| Rekin Pharma Private Limited | ₹3.53 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | New Delhi, Delhi, India |
| Vivin Instruments Private Limited | ₹3.53 Cr (FY 2020) | •••• | •••• | -58.0% | •••• | Mumbai, Maharashtra, India |
| Sapigen Biologix Private Limited | ₹3.53 Cr (FY 2025) | •••• | •••• | 87.0% | •••• | Bhubaneswar, Odisha, India |
Peers are the five companies nearest above and the five nearest below Plus India Formulation by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Plus India Formulation Private Limited
Plus India Formulation has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sudhakara Reddy Kalakota | Director | 14 Sep 2021 | 5 Years 0 Months | Current |
| Rama Devi Kalakota | Director | 14 Sep 2021 | 5 Years 0 Months | Current |
Ownership and Shareholding of Plus India Formulation Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Plus India Formulation Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jan 2024 | Others | ₹50 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Plus India Formulation Private Limited
Plus India Formulation Private Limited has a workforce of 0 employees as of Apr 05, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Plus India Formulation Private Limited
Plus India Formulation Private Limited has 2 board changes on record since 2021: 2 appointments. The latest: Rama Devi Kalakota was appointed as Director on 14 Sep 2021.
Credit Ratings, Litigation & Regulatory Alerts for Plus India Formulation Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Plus India Formulation Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Plus India Formulation Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Plus India Formulation Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Plus India Formulation Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Plus India Formulation Private Limited
Plus India Formulation is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 14 September 2021 (5+ years old) and is registered under CIN U52110TG2021PTC154953.
Plus India Formulation reported revenue of ₹3.55 Cr for FY 2025 (up 5% YoY).
Plus India Formulation has 2 current directors:
- Sudhakara Reddy Kalakota - Director
- Rama Devi Kalakota - Director
Plus India Formulation reported a net profit of ₹3.28 Lakh (net margin 0.9%) and EBITDA of ₹4.5 Lakh (EBITDA margin 1.3%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Plus India Formulation is 65% over three years. In the latest year (FY 2025) revenue rose 5%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Plus India Formulation is U52110TG2021PTC154953. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Plus India Formulation was incorporated on 14 September 2021, making it 5+ years old. It is registered with the Registrar of Companies, Hyderabad.
The peers of Plus India Formulation by revenue are Genext Healthcare Private Limited, Shirr Pharmaceuticals Private Limited, Laxor Pharma Private Limited, Aayush Medication Private Limited, Lohitha Chemtek Private Limited and 5 more, all in the Pharma industry (Formulations).
Rama Devi Kalakota was appointed as Director on 14 Sep 2021. Sudhakara Reddy Kalakota was appointed as Director on 14 Sep 2021.
The registered office of Plus India Formulation is at First Floor Plot No 15 Pradampuri Colony Kapra Ecil Post, Hyderabad, Telangana, India – 500062.
Plus India Formulation has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh.